126 related articles for article (PubMed ID: 1440938)
1. The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.
Gebbia V; Citarrella P; Miserendino V; Valenza R; Borsellino N; Pesta A; Pettit R; May S
Tumori; 1992 Jun; 78(3):167-71. PubMed ID: 1440938
[TBL] [Abstract][Full Text] [Related]
2. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Jones RJ; Sharkis SJ; Miller CB; Rowinsky EK; Burke PJ; May WS
Blood; 1990 Mar; 75(6):1319-23. PubMed ID: 2310830
[TBL] [Abstract][Full Text] [Related]
3. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
Grant S; Pettit GR; Howe C; McCrady C
Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.
van der Hem KG; Dräger AM; Odding JH; Langenhuijsen MM; Huijgens PC
Leuk Res; 1995 Jan; 19(1):7-13. PubMed ID: 7837820
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.
Vrana JA; Wang Z; Rao AS; Tang L; Chen JH; Kramer LB; Grant S
Leukemia; 1999 Jul; 13(7):1046-55. PubMed ID: 10400420
[TBL] [Abstract][Full Text] [Related]
6. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
7. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia.
Lilly M; Brown C; Pettit G; Kraft A
Leukemia; 1991 Apr; 5(4):283-7. PubMed ID: 2027297
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung RL; Pearson JW; Beckwith M; Longo DL
Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
[TBL] [Abstract][Full Text] [Related]
9. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
10. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
Prendiville J; McGown AT; Gescher A; Dickson AJ; Courage C; Pettit GR; Crowther D; Fox BW
Br J Cancer; 1994 Oct; 70(4):573-8. PubMed ID: 7917900
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
[TBL] [Abstract][Full Text] [Related]
14. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Reddy KB; Al-Katib AM
Int J Mol Med; 2000 Feb; 5(2):165-71. PubMed ID: 10639596
[TBL] [Abstract][Full Text] [Related]
15. Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.
van der Hem KG; Schuurhuis GJ; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1996 Sep; 20(9):743-50. PubMed ID: 8947584
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
McCrady CW; Li F; Pettit GR; Grant S
Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
[TBL] [Abstract][Full Text] [Related]
17. Structural modifications of bryostatin 2.
Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials referral resource. Clinical trials using bryostatin-1.
Pluda JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 May; 10(5):740-2. PubMed ID: 8738829
[No Abstract] [Full Text] [Related]
19. Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM).
Grant S; Pettit GR; McCrady C
Exp Hematol; 1992 Jan; 20(1):34-42. PubMed ID: 1374343
[TBL] [Abstract][Full Text] [Related]
20. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; van der Hem KG; Odding JH; Dräger AM; Ossenkoppele GJ
Br J Cancer; 1999 Mar; 79(9-10):1406-12. PubMed ID: 10188883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
